ESMO精准医学工作组关于转移性癌症NGS使用的推荐
ESMO精准医学工作组基于现有证据提出转移性癌症NGS使用的三级推荐。推荐在晚期非鳞非小细胞肺癌、前列腺癌、卵巢癌和胆管癌中常规使用NGS,在结肠癌中NGS可作为PCR的替代,并推荐在宫颈癌、分化良好/中分化神经内分泌肿瘤、唾液腺癌、甲状腺癌和外阴癌中检测TMB以预测帕博利珠单抗疗效。
要点
- 晚期非鳞NSCLC、前列腺癌、卵巢癌和胆管癌推荐常规NGS检测。
- 结肠癌中NGS可作为PCR的替代方案。
- 宫颈癌、神经内分泌肿瘤等特定瘤种推荐检测TMB预测帕博利珠单抗疗效。
核心结论
- ESMO提出三级推荐框架指导转移性癌症的NGS临床应用。
- 在特定瘤种中推荐常规NGS检测,并推荐特定瘤种检测TMB。
- 超适应症用药需有国家或地区层面的准入程序和决策程序。
研究设计与样本
- ESMO精准医学工作组基于当前证据提出的推荐报告。
主要发现
- 晚期非鳞NSCLC、前列腺癌、卵巢癌和胆管癌中常规NGS推荐,大panel在小panel基础上增加可接受成本时可使用。
- 结肠癌中NGS可作为PCR的替代。
- 基于KN158试验,宫颈癌、分化良好和中等分化神经内分泌肿瘤、唾液腺癌、甲状腺癌和外阴癌中TMB-high预测帕博利珠单抗应答,推荐检测TMB。
关键数值与推荐
- 晚期非鳞NSCLC、前列腺癌、卵巢癌和胆管癌:常规NGS推荐。
- 结肠癌:NGS可作为PCR的替代。
- 宫颈癌、分化良好和中等分化神经内分泌肿瘤、唾液腺癌、甲状腺癌和外阴癌:推荐检测TMB。
临床怎么用
- 对推荐瘤种常规进行NGS检测以指导治疗决策。
- 在特定瘤种中检测TMB以筛选可能从帕博利珠单抗获益的患者。
- 超适应症基因组匹配用药需在国家或地区层面有准入程序和决策程序。
- 临床研究中心应将多基因测序作为筛选临床试验患者的工具并前瞻性收集数据。
局限性
- 大panel可能仅带来少数有临床意义的应答者。
- 患者和医生可共同决定订购大panel,但需无额外公共医疗费用且患者知晓获益可能性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about its use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three levels of recommendations for the use of NGS. Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma. In these tumours, large multigene panels could be used if they add acceptable extra cost compared with small panels. In colon cancers, NGS could be an alternative to PCR. In addition, based on the KN158 trial and considering that patients with endometrial and small-cell lung cancers should have broad access to anti-programmed cell death 1 (anti-PD1) antibodies, it is recommended to test tumour mutational burden (TMB) in cervical cancers, well- and moderately-differentiated neuroendocrine tumours, salivary cancers, thyroid cancers and vulvar cancers, as TMB-high predicted response to pembrolizumab in these cancers. Outside the indications of multigene panels, and considering that the use of large panels of genes could lead to few clinically meaningful responders, ESMO acknowledges that a patient and a doctor could decide together to order a large panel of genes, pending no extra cost for the public health care system and if the patient is informed about the low likelihood of benefit. ESMO recommends that the use of off-label drugs matched to genomics is done only if an access programme and a procedure of decision has been developed at the national or regional level. Finally, ESMO recommends that clinical research centres develop multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development, and prospectively capture the data that could further inform how to optimise the use of this technology.
引用
- Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020. PMID: 32853681. doi:10.1016/j.annonc.2020.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。